Physician profile
Desiree Weems
NPI 1144695313
$1,947.03
in general payments reported to CMS, 2019-2025
12 companies · $512 in 2025
The $512 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $445 · 2023: $340 · 2024: $369 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $490.17 | 2022-2024 | Ingrezza |
| Abbvie INC. | $465.77 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $146.29 | 2024 | |
| Medicure Pharma INC. | $141.45 | 2025 | Zypitamag |
| Mayne Pharma Commercial LLC | $121.83 | 2025 | |
| Abiomed | $121.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.03 | 2022 | |
| Viiv Healthcare Company | $103.50 | 2025 | Apretude |
| Alkermes, INC. | $100.00 | 2022 | |
| Emd Serono, INC. | $94.94 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.64 | 2025 | Airsupra |
| Therapeuticsmd, INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Weems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.